Noema Pharma announces first patient dosed in Phase 2b LibraTN study of mGluR5 inhibitor NOE-101 in trigeminal neuralgia
22 févr. 2022 08h00 HE
|
Noema Pharma
Study evaluating the efficacy of NOE-101 for management of pain associated with trigeminal neuralgia BASEL, Switzerland, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical stage...
Noema Pharma Announces FDA Investigational New Drug Authorization for Phase 2b LibraTN Study of mGluR5 Inhibitor NOE-101 in Trigeminal Neuralgia
14 févr. 2022 08h00 HE
|
Noema Pharma
Study to evaluate efficacy of NOE-101 for management of pain associated with trigeminal neuralgia BASEL, Switzerland, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical stage...
Noema Pharma to Host Key Opinion Leader Webinar on Trigeminal Neuralgia “Trigeminal Neuralgia? You are not alone”
08 févr. 2022 08h00 HE
|
Noema Pharma
Friday, February 11th 2012 - 12 pm EST / 6 pm CET Featuring Dr. Joanna Zakrzewska from University College London Hospital andTerence J. Coderre, Ph.D. from McGill University BASEL, Switzerland,...
Noema Pharma Hosting Key Opinion Leader Webinar on Stuttering
08 déc. 2021 02h00 HE
|
Noema Pharma
BASEL, Switzerland, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announced that it will host a...
Noema Pharma expands its Board of Directors with the appointments of Catherine Moukheibir and Ilise Lombardo
09 nov. 2021 08h55 HE
|
Noema Pharma
BASEL, Switzerland, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of...
Noema Pharma appoints Jeffrey Jonas as Independent Chairman of the Board of Directors
04 oct. 2021 02h00 HE
|
Noema Pharma
BASEL, Switzerland, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Noema Pharma AG, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of...
Noema Pharma to attend Swiss Biotech Day and the UBS Biotech Private Company Symposium in September 2021
02 sept. 2021 03h00 HE
|
Noema Pharma
BASEL, Switzerland, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces it will attend two...
Noema Pharma Initiates Phase 2a Allevia Study of PDE10A Inhibitor NOE-105 in Tourette Syndrome
05 août 2021 01h30 HE
|
Noema Pharma
First Noema clinical trial, with asset in-licensed from Roche with strong clinical safety packageNoema advancing potentially life-changing therapeutics for patients without satisfactory treatments ...
Noema Pharma to Attend Investor Conferences in June and July 2021
31 mai 2021 02h00 HE
|
Noema Pharma
BASEL, Switzerland, May 31, 2021 (GLOBE NEWSWIRE) -- Noema Pharma (“Noema”) AG, a Swiss clinical-stage company targeting orphan neurological disorders, today announces it will attend several...
Noema Pharma raises CHF54 million in Series A financing round led by Sofinnova Partners and Polaris Partners
01 déc. 2020 02h00 HE
|
Noema Pharma
In-licensing of four clinical-stage product candidates to treat orphan neurological disordersHighly experienced team leverages latest scientific discoveries in neuroscienceFinancing will advance the...